Guidelines for the safe administration of high-dose interleukin-2.
High-dose interleukin-2 (IL-2) results in objective clinical regression of metastatic cancer in 15% to 17% of patients with melanoma and renal cell carcinoma. Durable complete regression of all metastases is seen in 6% to 8% of patients. Based on these findings, the U.S. Food and Drug Administration has approved the use of high-dose IL-2 for the treatment of patients with metastatic melanoma and renal cell carcinoma. Interleukin-2 administration is associated with many different side effects, and after many years of use, clinicians have learned how to safely administer high-dose IL-2. This article details practical guidelines for the safe administration of high-dose IL-2.
Schwartzentruber
D J
DJ
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. djs@nih.gov
D019559:Capillary Leak Syndrome / Q000139:chemically induced / Q000175:diagnosis; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D005440:Fluid Therapy; D006801:Humans; D007022:Hypotension / Q000209:etiology / Q000628:therapy; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D010996:Pleural Effusion / Q000139:chemically induced / Q000628:therapy
D007376:Interleukin-2